Dark

Check out our Dark Pool Levels

ATRX
ADHERA THERAPEUTICS INC
stock OTC

Inactive

Jun 17, 2025

0.000001USD-99.000%(-0.000099)125

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 20, 2022

08:45AM EST Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace GlobeNewswire Inc

Nov 22, 2021

10:00AM EST Adhera Therapeutics Receives Notice of Allowance for New Canadian GlobeNewswire Inc

Nov 8, 2021

09:15AM EST Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Companys Board of Directors. GlobeNewswire Inc

Oct 20, 2021

09:35AM EDT Adhera Therapeutics Expands Relationship with Melior GlobeNewswire Inc

Oct 15, 2021

10:22AM EDT Manufacturing Commences on Adheras MLR-1019 for GlobeNewswire Inc

Oct 4, 2021

09:15AM EDT Adhera Receives European Patent Covering MLR-1019 and Derivatives GlobeNewswire Inc

Sep 13, 2021

10:28AM EDT Adhera Therapeutics Provides Insight on Corporate Strategy, GlobeNewswire Inc

Sep 9, 2021

09:05AM EDT Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Andrew G. Reaume, Ph.D., MBA to the Companys Board of Directors. GlobeNewswire Inc

Aug 24, 2021

09:20AM EDT -- Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 480,000 patients in U.S.) -- Laboratory and clinical research support MLR-1023 as the worlds first safe, effective beta cell proliferative agent -- Adhera will leverage existing data to initiate a Phase 2 trial in Type 1 diabetes patients GlobeNewswire Inc

Jun 7, 2021

08:45AM EDT -- Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb a drug previously sold in Europe for 37 years for Parkinsons Disease -- MLR-1019, a Phase 2-ready product, could have substantial benefits over todays Parkinsons drugs, including being the first to address both movement and non-movement symptoms GlobeNewswire Inc

Apr 23, 2021

09:00AM EDT Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors GlobeNewswire Inc

Share